CTOs on the Move

Psychemedics

www.psychemedics.com

 
Psychemedics (NASDAQ: PMD) is the world`s leading drug testing company using hair for the detection of drugs of abuse. Psychemedics has been successfully operating for 30 years and thousands of corporations worldwide currently rely on Psychemedics` patented hair analysis technology for their pre-employment and employee drug screening. Psychemedics` clients include over 10% of the Fortune 500, some of the largest police departments in America, Federal Reserve Banks, and schools.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Martin Curland
Vice President Information Technology and Chief Information Security Officer Profile

Similar Companies

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syan Biosciences

Syan Biosciences is a Halethorpe, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celldex Therapeutics

Celldex Therapeutics is a Needham Heights, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMD Biosciences

EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.